Massive transfusions are accompanied by an increased incidence of a particularly aggressive and lethal form of acute lung injury (delayed transfusion-related acute lung injury) which occurs longer than 24 hours after transfusions. In light of recent reports showing that mitochondrial (mt)DNA damage-associated molecular patterns (DAMPs) are potent proinflammatory mediators, and that their abundance in the sera of severely injured or septic patients is predictive of clinical outcomes, we explored the idea that mtDNA DAMPs are present in transfusion products and are associated with the occurrence of delayed transfusion-related acute lung injury.
T he recent paradigm shift in resuscitation of patients in hemorrhagic shock, using blood components in a manner which reconstitutes whole blood and limits the use of crystalloid, has given rise to a new form of transfusion-related acute lung injury (TRALI) termed "delayed" TRALI. 1, 2 The "traditional" form of TRALI is rare (1 in 5,000 transfusions), occurs after only one unit of transfusion, has immediate onset, and is often self-limiting with complete resolution. 3, 4 In contrast, the "delayed" form of TRALI is seen 48 hours to 72 hours after massive transfusions, occurs in over 50% of patients receiving multiple transfusions, and progresses to a nonresolving severe respiratory failure (i.e., acute respiratory distress syndrome [ARDS]). 2 Regardless of the clinical presentation, ARDS has emerged as the most frequent manifestation of multiorgan failure after massive transfusions. A better understanding of the mechanisms of delayed TRALI leading to the identification of discrete pharmacological targets for intervention is urgently needed and is the overall goal of this research.
Although traditional TRALI is often attributed to leukocyte antibodies in the donor blood directed against the recipient, the stark differences between the "traditional" and "delayed" forms of TRALI suggest a different pathogenesis. The notion that there are critical mediators present in transfused blood products which accumulate after massive transfusions is intuitively appealing in light of the direct correlation between the occurrence of ARDS (i.e., delayed TRALI) and the number of transfusions and/or storage life of the transfused products. 2, 5 In support of this "mediator concept," we recently reported that proinflammatory fragments of the mitochondrial (mt) genome, termed mtDNA damage-associated molecular patterns (DAMPs), can be detected in variable amounts in stored blood products. of its proteobacterial origin, the structure and proinflammatory effects of mtDNA are similar if not identical to bacterial DNA. Both propagate damage through TLR9-mediated activation of itinerant and resident inflammatory and other target cells. Administration of exogenous mtDAMPs to experimental animals, isolated lungs, and cultured cells recapitulates many elements of SIRS and multiorgan system failure, including acute lung injury. 8, 9 Finally, we and others have previously shown that serum levels of mtDNA DAMPs correlate with outcome in multiple patient populations. [9] [10] [11] [12] Against this background, we tested the hypothesis that in severely injured patients, ARDS after multiple transfusions is accompanied by a higher quantity of serum mtDNA DAMPs which is also associated with the quantity of proinflammatory mtDNA DAMPs transfused to the patient.
PATIENTS AND METHODS

Quantification of mtDNA in Transfused Blood Products
Fourteen consecutive severely injured patients (Injury Severity Score >15) older than 18 years requiring greater than three units of blood product transfusion within 48 hours of presentation were prospectively enrolled. Once blood product units were allocated for transfusion, aliquots of each unit was collected and stored at −20°C until processing, after which mtDNA quantification was performed for up to the first 10 units per patient. ABO blood type, donor sex, and product storage times were recorded. Within 12 hours of collection, samples from the transfusion products were then centrifuged at 1,200g for 25 minutes at 21°C, and 200 μL of the supernatant was decanted and processed using the Qiagen DNEasy kit (Qiagen Inc., CA) as previously described. 6, 10 After DNA elution, quantitative polymerase chain reaction (qPCR) was performed using the USB VeriQuest Fast SYBR Green qPRC Master Mix (Affymetrix, CA) per manufacturer's protocol, amplifying approximately 200-bp sequence corresponding to the ND6 region of the mitochondrial genome as previously described 6, 10 (ND6 Primers: Forward CCATCGCTG TAGTATATCCAA, Reverse TCGGGTGTGTTATTATTCTGA). Cumulative transfused mtDNA burden was determined by summing the mtDNA content for all transfused products calculated as the concentration in each tested aliquot multiplied by transfusion volume of the respective unit (350 mL for packed red blood cells (PRBC), 300 mL for fresh frozen plasma (FFP), and 250 mL for platelets).
Measurement of Serum mtDNA After Transfusion
A waiver of informed consent was approved by the University of South Alabama IRB per DHHS 45 CFR 46.116; all enrolled patients or their legal proxy were provided an information sheet describing the study protocol at earliest availability with the option to withdraw from the study. A 4-mL sample of peripheral blood was collected and placed into a citrated tube within 8 hours of initial transfusion and 24 hours to 48 hours afterward. Samples were immediately centrifuged at 1,200 g for 25 minutes at 21°C, after which 200 μL of the supernatant was decanted and processed for DNA quantification as described above. Patients were monitored during the course of care for development of ARDS per the Berlin definition. 13 Data were analyzed using Graphpad Prism software by analysis of variance (ANOVA) with Newman-Keuls posttest, unpaired t test, or linear regression, as dictated by the specific experimental design. Results are displayed as mean ± standard error and statistical significance was defined as P less than 0.05.
RESULTS
Characteristics of mtDNA DAMPs in Transfusion Products
Mitochondrial DNA was detected by qPCR in all three blood components examined (Fig. 1) , with FFP and platelets containing significantly more mtDNA than PRBCs (PRBC, 3.0 ± 0.4; FFP, 195.8 ± 58.8; Plt, 93.9 ± 24.3, p < 0.01) corroborating our initial report. 6 To determine the effect of storage life on extracellular mtDNA concentration, blood products were classified as young, moderate, or old based on relative shelflife; for PRBCs 0 week to 2 weeks, 2 weeks to 4 weeks, and 4 weeks to 6 weeks respectively; for plasma, 0 month to 4 months, 4 months to 8 months, and 8 months to 12 months, respectively; for platelets, 1 day to 2 days, 3 days to 4 days, and 5 days to 7 days, respectively. Packed red blood cells and FFP differed by shelf-life in mtDNA concentration but individual strata did not significantly differ by Newman-Keuls posttest (PRBC: young, 2.2 ± 0.6; moderate, 3.5 ± 0.8; old, 2.9 ± 0.6; p = 0.009; FFP: young, 265.2 ± 83.5; moderate, 87.1 ± 39.1; old, 19.3 ± 7.6; p < 0.001). Blood products were also categorized based on ABO donor blood type (Fig. 2) . Variances significantly differed for all products by ANOVA; however, ABO types did not differ by Newman-Keuls posttest (A, 189.4 ± 81.1; B, 33.7 ± 21.1; AB, 15.0 ± 5.4; O, 49.3 ± 16.2; p < 0.001). ABO type exhibited similar trends in total mtDNA content when PRBC, FFP, and platelets were individually analyzed (data not shown). Blood products were also examined based on donor sex (Fig. 3) . Packed red blood cells did not differ between men and women (male, 2.5 ± 0.5 vs. female, 3.4 ± 0.7). Female FFP had greater mtDNA content relative to male FFP (male, 178.6 ± 67.3 vs. female, 690.5 ± 128.1; p = 0.046), and female platelets had a similar tendency toward higher mtDNA content, but this did not reach statistical significance (male, 33.86 ± 5.412 vs. female, 198.5 ± 172.5; p = 0.29). 
Characteristics of Enrolled Patients and Serum mtDNA Concentrations
Enrolled patients were followed up for development of ARDS after more than 3 transfusions with the intent of determining if the development of ARDS (i.e., delayed TRALI) was associated with the amount of mtDNA DAMPs transfused to the patient and/or serum concentration. There were 14 patients enrolled, and five met the criteria for ARDS. Patient characteristics did not significantly differ between groups (Table 1) . Within 8 hours of presentation, serum mtDNA DAMPs did not differ significantly between groups; however, by 24 hours to 48 hours after presentation, those who developed ARDS had higher levels of serum mtDNA DAMPs than patients who did not (Fig. 4) .
Association of Transfused mtDNA DAMPs and Serum Concentration
Patients who developed ARDS received significantly more mtDNA DAMPs during transfusion than patients who did not (no ARDS, 1.9 Â 10 4 ± 6.6 Â 10 3 ng/mL vs. ARDS, 3.8 Â 10 4 ± 9.6 Â 10 3 ng/mL; p < 0.05) despite receiving similar volumes of transfusion products ( Table 1 ). The amount of transfused mtDNA was then compared with serum levels. As depicted in Fig. 5 , the serum mtDNA concentration after transfusion correlated with cumulative transfused mtDNA (R 2 = 0.74, p < 0.01).
DISCUSSION
Despite improvements in resuscitation and supportive care, pharmacologic strategies to prevent or reverse ARDS have to date been unsuccessful. This deficiency has been ascribed to the prospect that key pathways integrating cellular responses to systemic inflammation have not yet been identified. In this context, multiple lines of emerging evidence converge on the idea that mitochondria orchestrate responses to injurious and inflammatory stimuli by releasing a family of mediators known collectively as mtDAMPs, including formyl and other peptides as well as mtDNA fragments.
14 The latter is conspicuous in light of observational studies in human subjects showing that serum levels of mtDNA DAMPs are predictive of outcomes in critically ill, septic, or severely injured patients. [10] [11] [12] 15, 16 In addition, a number of experiments in animal and cell culture models show that mtDNA is elaborated into the extracellular environment by inflammatory injury and that administration of exogenously produced mtDNA DAMPs recapitulates many of the attributes of ARDS and multiorgan failure seen in human subjects. 8, 9, 17, 18 Interventions that block the actions of exogenously administered mtDNA DAMPs, such as inhibition of the receptor on which mtDNA acts, TLR9, or DNase to enhance DNA degradation, also prevent lung injury evoked by inflammatory stimuli. 8 Finally, exogenous mtDNA DAMPs cause mtDNA damage and release of more mtDNA DAMPs, thus pointing to the intriguing prospect that accumulation of serum mtDNA DAMPs, regardless of the inciting event, could activate a feed-forward cycle that persists even after termination of the initiating stimulus. 8, 19 Here, we tested the idea that the amount of mtDNA DAMPs administered via transfusion to patients after severe injury is associated with the occurrence of ARDS. Of particular importance to our conclusions is the fact that not only were patients prospectively enrolled and displayed comparable severities of injury but all patients enrolled in this proof-of-concept study received similar total volumes of blood products. Against this background, although serum concentrations of mtDNA DAMPs measured within 8 hours of admission were similar between groups, mtDNA DAMPs measured 24 hours to 48 hours after admission were significantly higher in individuals developing ARDS relative to those who did not (Fig. 4) . Because the serum concentration of mtDNA DAMPs was closely correlated with the amount of mtDNA given during transfusion (Fig. 5) , and because observations in multiple animal and cell culture models show that exogenous mtDNA DAMPs mimic key attributes of ARDS, these data provide perhaps the most persuasive support in human subjects heretofore available that mtDNA DAMPs may be associated with the development of ARDS after massive transfusions.
Our data do not permit conclusions about which mtDNA fragment, or indeed, which mt-derived DAMP contributes to ARDS in the setting of massive transfusion. There are previous reports of synergy between mtDNA and other mitochondrial proteins. 20 It is also unknown how much the quantity of crystalloid used during resuscitation, prior ischemia-reperfusion injury, or other inflammatory inciting events contribute to the development of ARDS. Other inflammatory mediators interacting with mtDNA DAMPS also present in transfusion products or generated in the patient as a result of transfusion are other possible events adding complexity to the proposal that mtDNA DAMPs are important in the evolution of transfusion-related ARDS. [21] [22] [23] Finally, the pathways governing the disposition of circulating mtDNA are almost completely unknown, as are the determinants of the response to transfused mtDNA DAMPs. Circulating DNase is one possible pathway of degradation, but other mechanisms of clearance cannot be discounted. Addressing these issues will require studies of a different design than those used in the present report.
We detected impressive differences in the amount of mtDNA in the three transfusion products. These differences are likely attributable to whether the product was leuko-reduced and whether the constituents of the product contained mitochondria. For example, because RBCs do not contain mitochondria and are subjected to leukocyte reduction, it is not surprising that the concentration of mtDNA detected in this transfusion product was lowest among the three tested. The highest concentrations of mtDNA DAMPs were detected in FFP. In this instance, we postulate that the high levels of mtDNA DAMPs are likely due to the fact that FFP is not subjected to leukocyte reduction and thus contain a large number of WBCs. In addition, because FFP is frozen immediately after procurement and thawed immediately before transfusion, we suspect that mtDNA DAMPs are formed as a result of leukocyte rupture during thawing.
Substantial amounts of mtDNA DAMPs were also detected in platelets, a finding not particularly surprising since platelets contain large numbers of mitochondria DNA. In addition, because the mature platelet does not contain a nucleus, it lacks the machinery to repair oxidative mtDNA damage, thereby creating a condition wherein platelet mtDNA may undergo cycles of replication and degradation. 24 In light of these considerations, it is tempting to speculate that an oxidant-enriched environment in stored platelets 25, 26 leads to oxidative mtDNA damage and attendant elaboration of mtDNA DAMPs, 8, 17 which may, in turn, contribute to the limited shelf-life of platelets. 27 The impact of blood donor sex on complications after transfusion has been investigated for decades. Older publications on this subject tend to focus on antibody-mediated TRALI, which may have little bearing on understanding the relationship between transfusion and the phenotype of delayed TRALI. However, recent large retrospective studies have demonstrated sexbased differences in mortality after high plasma ratio transfusions, and that female recipients of transfusion have worse outcomes following the newer guidelines. 28 Provocatively, we found that FFP from females displayed higher mtDNA DAMP concentrations; no sex-related differences were detected in LR-PRBCs. These findings, in concert with the previously mentioned report, confirm that a sex-based predilection toward increased inflammatory responses likely exists and that mtDNA DAMPs may contribute to this reaction. Another interesting finding in our study was that mtDNA DAMP concentrations differ between ABO blood types. For example, type A donors tended to have higher concentrations of mtDNA DAMPs compared with other ABO types, regardless of the specific stored blood component. Indeed, previous studies have shown that patients with blood type A are more likely to develop ARDS after sepsis and trauma. 29 Figure 5 . Cumulative transfused mtDNA DAMPs were compared with posttransfusion serum quantities. A linear correlation was noted between transfusion burden and serum levels (R 2 = 0.74, p < 0.01). Those who developed ARDS are marked in red triangles; those who did not are marked in black circles.
In conclusion, these data show that FFP and platelets contain large amounts of extracellular mtDNA, that the amount of mtDNA DAMPs administered during transfusion may be a contributor of serum mtDNA DAMP levels, and that serum levels of mtDNA DAMPs after multiple transfusions may predict the development of ARDS. Collectively, these findings support the idea that mtDNA DAMPs in transfusion products are associated with the incidence of ARDS after massive transfusions. Finally, to determine the true value of serum mtDNA DAMP measurements as predictive biomarkers for the evolution of ARDS and MODS in the setting of severe injury, it will be ultimately be necessary to standardize means for measuring and reporting mtDNA abundance and apply these to a substantial patient cohort. 
Dr. Carl J. Hauser (Boston, Massachusetts): This paper advances the prior work of our new member, Jon Simmons, here on the significance of mitochondrial DAMPs in injury and combines two important threads of inquiry.
First, we know that mitochondrial DNA circulates at high level after human injury. It activates neutrophils. And it can give rodents ARDS. In other models, however, mitochondrial DNA is clearly a potent immune suppressive so this is a complex relationship.
But mitochondrial DNA is clearly a marker in the circulation, not just for itself but for other mitochondrial DAMPs like formal peptides as well as non-mitochondrial DAMPs like heat shock proteins, all of which belong inside cells, not outside cells.
All activate innate immunity when released from injured cells and mitochondrial DNA is clearly a marker for their presence. As this group and others have shown, circulating mitochondrial DNA is very clearly associated with inflammation and death after trauma and in critical illness.
Secondly, trauma patients get blood and blood products are inflammatory. In addition, though, there is a rare acute and rather self-limited form of acute lung injury that occurs after fresh frozen transfusions from women who are sensitized to fetal neutrophil antigens. That has been TRALI. It's also called immune TRALI in the hematology literature.
Some TRALI has, some hematologists have also postulated that there is a non-immune form of TRALI and that it occurs after trauma, sepsis and other neutrophil-activating events, which has been termed "non-immune," although I would argue that it is simply innate immune TRALI rather than classical immunity-induced TRALI.
It's unclear, though, in this setting exactly what causes traumatic ARDS and whether it's DAMPs from injury or our treatments that are most to blame.
My impression is the authors have made an important contribution looking at blood products as a potential source of mitochondrial DAMPs. They clearly do show fresh frozen plasma and platelets are sources of mitochondrial DNA and, by inference, who knows what else. That's important work.
The paper also reminds us that fresh frozen is not a-cellular. The white count is a few percent of what it is in blood but that's plenty to be a source of DAMPs.
But does this paper actually prove that fresh frozen causes ARDS by transfusing patients with mitochondrial DNA? I would say that there is a reasonable association and it suggests that mitochondrial DNA makes a significant contribution and, also, self-perpetuation rather than decay of the mitochondrial signal, as we have already shown in primates, is critical.
Some of the speculation in this paper deserves special mention, like the finding that Type A blood, as well as blood products from females, are higher in DAMPs. Those observations are not conclusive but they are fascinating.
I have four simple questions: First, why not simply assay for mitochondrial DNA pre-, post-and at intervals after product administration to assess their contribution to plasma mitochondrial DNA directly and then to look at mitochondrial DNA decay?
Second, have you assayed recipient blood or donorspecific blood-requires making primers-but for the same reason?
Third, have you looked for the contribution of microparticles to blood product mitochondrial DNA? That's very easy. You simply ultracentrifuge it.
Lastly, the authors suggest that we leukoreduce all fresh frozen, just the units from women? Units from blood Type A women? Or perhaps from Type A women of which we have a number out here?
I'd like to congratulate the authors on the important conceptual events and to thank the Association for the privilege of the floor.
Dr. Christopher Barrett (Boston, Massachusetts): Thank you for this wonderful talk, Dr. Simmons, this is a really innovative paper. I had a question regarding your future studies as to whether you had considered broadening the search for other contributing mechanisms such as measuring things like C5 levels in the FFP prior to transfusion and then subsequently measuring C5a levels in the patients over time, or alternatively looking at some of the inflammatory chemokines that are normally bound to the surface of RBC's via the Duffy Antigen Receptor for Cytokines, such as IL-8, in your packed RBC's and then following levels in patients after transfusion? For example, a fresh infusion of C5 by way of FFP may be able to drive an inflammatory process like ARDS in an injured person where complement regulation is poor and the coagulation system has been activated and is capable of direct C5 cleavage to C5a through plasmin, Factor Xa, thrombin and others. Thank you again for this really innovative paper and I look forward to reading your future work in this field. Dr. Bryce R.H. Robinson (Seattle, Washington): This is really fascinating work and a very strong presentation.
I think it's important to understand that both in the PROMMTT and PROPPR trials it wasn't the blood, plasma, or platelets that were independently associated with hypoxemia or ARDS, but rather the magnitude of the crystalloid exposure. Shouldn't you account for this important variable independently and its interaction with DAMPs from the blood?
One secondary comment that I think Dr. Hauser already alluded to is the inclusion of microparticles in these types of studies. It has been previously reported that the budding of microparticles from packed red blood cells and platelets is a dynamic process and a significant contributor to cytokine generation during the inflammatory cascade. Did you consider the interaction of blood-specific microparticles with the DAMPs?
Dr. Zsolt J. Balogh (Newcastle, Australia): Congratulations for this great study.
My first question is-your 14 patients very clearly managed to show that ARDS patients had a much worse, a much higher level of mitochondrial DNA. Were they consecutive patients or had they been selected? Because we have a much larger cohort and we couldn't find a real difference in mitochondrial DNA concentration in SIRS, MOF and ARDS.
My second question is that the timely relationship with transfusion and the development of ARDS, when we monitored these patients to three, four, five days the mitochondrial DAMPs are actually increased in Day 3 and Day 5 and weren't associated with any further injury, any further surgery. These patients didn't get further transfusion but been in hospital and been in ICU.
Thank you very much. Dr. David J. Dries (Saint Paul, Minnesota): Congratulations to the authors on an outstanding study. I ask if the criteria for ARDS in this trial is based on the recent Berlin definitions? My other questions relate to the blood products administered. Does the likelihood of finding mitochondrial DNA DAMPs increase with duration of blood storage? Perhaps another message from this work is that we need to reconsider empiric 1:1:1 blood component blood administration and individualize to patient needs. Thank you.
Dr. Jon D. Simmons (Mobile, Alabama): Thank you, Dr. Hauser, for your review and many insightful comments. This is a proof-of-concept study and many of your remarks are about experiments that we are currently performing or planning to do.
Regarding the pre-and post-measurements. This was just a proof-of-concept study to ensure feasibility and provide evidence that a robust well-designed prospective study was warranted. We are currently enrolling patients for both pre-and post-transfusion levels so hopefully we will know the ultimate disposition of mitochondrial DNA DAMPS in this patient population in the near future.
Regarding your comment about determining whether or not the serum levels of measured mtDNA DAMPs were from the actual patient or from the donor blood product, meaning endogenous or exogenous, that's probably pretty difficult to do. I suppose that you could look for SNIPS (single nucleotide polymorphisms) in the patient's mitochondrial genome and compare this to the transfused blood products via PCR to develop a ratio between endogenous/exogenous but that is beyond the scope of this study. However, the results of such an experiment would be intriguing.
We did not specifically measure for microparticles in this study but I believe that any microparticles present would be within the pellet after the centrifugation steps that were performed and therefore unlikely contributed to our measurement of extracellular mtDNA. We do have someone in our lab that currently works with microparticles and have preliminary evidence that microparticles do contain mtDNA, but whether and how they contribute to the measurement of extracellular mtDNA is unclear at present. One interesting finding that has been reported is that unique surface markers on microparticles do exist, which may allow for determination of the cell type from which they originated. In the future, one may be able to determine the actual source of each microparticle which may also provide insight into the source of many different inflammatory mediators.
Regarding crystalloid and PROPPR trial comment, we did not control for the amount of crystalloid in this study. Indeed, crystalloid is inflammatory. However, we have previously shown that upon arrival to the emergency department, when low amounts of crystalloid were given, there is still a significant difference in serum concentrations of mtDNA DAMPs between survivors and non-survivors. So crystalloid is likely not the cause of the inflammatory milieu that creates endogenously-formed mitochondrial DNA DAMPs. Many still believe that most of the extracellular mtDNA that is being measured in this population is a product of cellular rupture from trauma. It's now pretty clear there is an inflammatory mechanism whereby the cell ejects mitochondrial DNA and other inflammatory mediators (i.e. DAMPs) without committing apoptosis. There is still a lot of unknowns about the formation and disposition of mtDNA DAMPs but our group and others are working on it.
Regarding consecutive patients, we intended to enroll consecutive patients. To the best of my knowledge we did this. There is a possibility that they weren't actually consecutive but it should be pretty close.
Regarding the question about severe ARDS, yes, these were patients with severe ARDS. One thing that I did notice is that the P-to-F ratios would vary in this cohort from day to day. Both groups had injury severity scores on average of 25 and received more than 10 units of blood products. So, the lung inflammation varied in the entire cohort but those included in the ARDS group definitely had severe ARDS.
Regarding the comment on storage lesions, which is the next aim of this particular grant. We are currently examining the role of storage-time of the blood products in comparison to the accumulation of mitochondrial DAMPs and other inflammatory mediators within the products.
I'd like to again thank the AAST with the opportunity to present this work.
